1998). Toxicol. Sci. 45,[225][226][227][228][229][230][231][232] Felbamate, 2-phenyl-l,3-propanediol dicarbamate, is a novel anticonvulsant that is effective against both chemically and electrically induced seizures in laboratory animals. Acute, subchronic, and chronic studies were conducted in mice, rats, and dogs to establish a preclinical safety profile for this drug. Clinical signs following single intraperitoneal doses included hypoactivity, tremors, decreased muscle tone, ataxia, prostration, and labored breathing. Death was observed after intraperitoneal but not oral administration. A consistent drug-related effect noted in all multiple-dose studies with this compound was decreased body weight and food consumption. The only other consistent change noted in multiple-dose studies with felbamate was an increase in liver weight (relative and absolute) in the rat and dog which was accompanied in some cases by increases in serum enzyme levels. No histopathological changes were observed in the liver that could explain these elevated serum enzyme levels. Based on the results of these studies it was concluded that long-term administration of felbamate in human clinical trials was warranted, o IWS soda; of Toxicology.
INTRODUCTION
Felbamate, 2-phenyl-l,3-propanediol dicarbamate ( Fig. 1) , is a novel antiepileptic that is effective against both chemically and electrically induced seizures in laboratory animals (Swinyard et ai, 1986) . This effect has also been demonstrated in human clinical trials (Leppik et ai, 1991; Sachdeo et ai, 1991; Ritter et ai, 1993) and the compound was recently approved for marketing (July 1993, Felbatol) . In addition to its antiepileptic effects, it has also shown activity in in vitro (Wallis et ai, 1992) and in in vivo ) models of hypoxic brain damage. There is evidence to indicate that felbamate interacts at the strychnine-insensitive glycine recognition site on the NMDA receptor-ionophore complex which may, in part, account for both its anticonvulsant and neuroprotectant activities (McCabe et al., 1993; Wallis and Panizzon, 1993; White, et ai, 1994) . Acute, subchronic, and chronic studies were conducted in mice, rats, and dogs to establish a preclinical safety profile for this drug and the results are reported herein.
METHODS

Chemicals
Hydroxypropyl cellulose, KJucel, type GF or LF was purchased from Hercules Incorporated (Wilmington, DE) . Sterile water for injection was obtained from Abbott (N. Chicago, IL). Gelatin capsules were purchased from Associated Capsules Pvt. Ltd. (Kandivli, West Bombay, India). All batches of bulk drug used in these studies were certified by analytical testing to be 100 ± 2% pure. The compound was stable in hydroxypropyl cellulose for at least 24 h and in drug-diet admixtures and gelatin capsules for at least 2 weeks.
Animals
Acute Studies
Four-to five-week-old mice [Crl:CD-l(ICR)BR] and rats (Crl:CD(SD)BR] were purchased from Charles River Laboratories (Wilmington, MA) and quarantined for 1 week. At the time of dosing, male mice weighed 20-35 g and female mice weighed 20-30 g while male rats weighed 150-250 g and female rats weighed 130-180 g.
Subchronic Studies
Four-week-old rats [SIM(SD)fBR] were purchased from Simonsen Laboratory (Gilroy, CA) and quarantined for 3 weeks. At the time dosing was initiated, male rats weighed 116-164 g and female rats weighed 101-139 g. Beagle dogs, purchased from White Eagle Laboratories (Doylestown, PA) were 9 months old at the time dosing was initiated and weighed 9.2-13 kg for males and 7.1-10.8 kg for females. The dogs were quarantined for a period of 4 weeks prior to dosing.
Chronic Studies
Three-to four-week-old rats [Crl:CD(SD)BR] were purchased from Charles River Laboratories (St. Constant, Quebec, Canada) and quarantined for 1 week. At study initiation, male rats weighed 94-142 g and females weighed 79-116 g. Beagle dogs, purchased from White Eagle Laboratories, were 6 months of age at study initiation. Male dogs weighed 5.8-9.2 kg and females weighed 5.4-7.6 kg. The dogs were quarantined for a period of 4 weeks prior to dosing.
Observations
Acute Studies 2-Phenyl-1,3-propanediol dlcarbamate
Subchromc Studies
Rats were housed singly in solid stainless-steel cages containing Beta Chip hardwood bedding and fed Wayne Lab Blox F-6 certified chow. Dogs were housed singly in concrete runs and fed Kasco dry dog food each day.
Chronic Studies
Rats were housed singly in stainless-steel wire mesh cages and fed Prolab RMH 3200 rodent diet (Agway, Inc., Syracuse, NY). Dogs were housed singly in concrete runs and fed ANF/M dry dog food (Ross-Wells, Mequon, WI) each day.
All Studies
Food and water were available at all times except when animals were fasted prior to dosing or bleeding. The animals were maintained in environmentally controlled rooms with a 12-h photoperiod.
Dosing
Acute Studies
Compound was suspended in 1% (w/v) hydroxypropyl cellulose in sterile water for intrapentoneal injection and gavage dosing. In the mouse studies, compound was administered once orally with a 18-gauge ball-tipped gavage needle or once intraperitoneally with a 20-gauge 1 -in. needle at a volume of 0.2 ml per 10 g body wt. In the rat studies, compound was administered once orally with a 16-gauge ball-tipped gavage needle or once intraperitoneally with a 18-gauge 1 -in. needle at a volume of 1.0 ml per 100 g body wt. In oral studies, mice and rats were given 3000 and 5000 mg/kg. In intraperitoneal studies, mice received from 375 to 775 mg/kg; rats received from 1000 to 5000 mg/kg.
Subchronic Studies
For the rat study, compound was suspended in 1% (w/v) hydroxypropyl cellulose and administered (1 ml/100 g body wt) by gavage at dose levels of 0, 100, 300, and 1000 mg/kg, 7 days/week, for a period of 3 months. Compound was administered in gelatin capsules in the dog study at dose levels of 0, 250, 500, and 1000 mg/kg, seven days/week, for a period of 3 months.
Chronic Studies
In the rat study, compound was administered as a drug-diet admixture at concentrations to achieve dose levels of 0, 30, 150, and 600 mg/kg in the males and 0, 30, 150, and 300 mg/kg in the females for a period of 1 year. Concentrations of drug in diet were adjusted weekly to achieve die targeted dose levels. Compound was administered in gelatin capsules in the dog study at dose levels of 0, 30, 100, and 300 mg/kg, 7 days/week, for a period of 1 year.
Appearance and overt behavior were noted daily, body weight was measured on Days 7 and 14 of the studies, and gross tissue changes were observed at necropsy on Day 14.
Subchronic Studies
Three-month raL Appearance and overt behavior were recorded daily; body weight was determined weekly. Blood was collected from the caudal artery prior to dosing and during Weeks 5 and 9 of the study. At termination, blood for hematology parameters was obtained from the caudal artery and for clinical chemistry parameters blood was obtained from the abdominal aorta. Prior to dosing and during Weeks 5 and 9 of the study, the blood samples were analyzed for hematocrit, erythrocyte count, leukocyte count, hemoglobin, reticulocyte count, platelet count, differential leukocyte count, glucose, urea nitrogen, and alanine aminotransferase. Terminal blood samples were analyzed for the above plus prothrombin time, erythrocyte sedimentation rate, activated partial thromboplastin time, aspartate aminotransferase, CTeatinine, total protein, alkaline phosphatase, cholesterol, potassium, sodium, chloride, and total bihrubin. Twenty-four-hour urine samples were collected on ice-dry ice mixture from all rats prior to dosing and during Weeks 5, 9, and 13. These samples were analyzed for volume, pH, specific gravity, creatinine, osmolality, urea nitrogen, protein, bilirubin, glucose, occult blood, ketone, and microscopic sediment. At necropsy, organ weight was recorded for heart, adrenals, spleen, liver, brain, lungs, kidneys, ovaries, and testes with epididymides. Samples of these tissues and aorta, pituitary, thyroid/parathyroid, esophagus, stomach, duodenum, pancreas, lleum, jejunum, cecum, thymus, mesenteric lymph node, tracheobronchial lymph node, bone marrow, colon, salivary gland, spinal cord, sciatic nerve, trachea, urinary bladder, mammary gland, uterus, prostate, femur, thigh muscle, skin, eyes, and optic nerve were taken and processed for microscopic examination.
Three-month dog. Appearance, overt behavior, and food consumption were recorded daily; body weight was recorded weekly. Blood pressure, heart rate, and electrocardiograms were recorded prior to dosing and during Weeks 4, 8, and 13 of the study. Ophthalmoscopic examination was performed at the same intervals. Blood samples for drug level assays were collected during Weeks 4, 8, and 13 of the study. Blood samples collected prior to dosing and during Weeks 4, 8, and 13 of the study were analyzed for total erythrocyte count, hematocrit, hemoglobin, sedimentation rate, total leukocyte count, differential leukocyte count, platelets, prothrombin time, activated partial thromboplastin time, glucose, urea nitrogen, alanine aminotransferase, aspartate aminotransferase, total protein, creatinine, total bilirubin, sodium, potassium, chloride, A/G ratio, cholesterol, and uric acid. Twenty-four-hour urine samples collected at the same intervals were analyzed for pH, specific gravity, volume, color, character, glucose, ketone, protein, and microscopic sediment. At necropsy, organ weights were recorded for the kidneys, liver, lungs, ovaries, pituitary, spleen, testes, and thyroids. Samples of these tissues and skin, adrenals, abdominal aorta, inferior vena cava, femur, brain, cecum, cervical lymph nodes, colon, costochondral junction, duodenum, esophagus, eyes, gallbladder, heart, ileum, jejunum, mammary gland, mesenteric fat, mesenteric lymph node, pancreas, prostate, salivary glands, sciatic nerve, thigh muscle, sternum, stomach (cardiac, fundic, pyloric), spinal cord, thymus, trachea, urinary bladder, uterus, and all gross lesions were taken and processed for microscopic examination.
Chronic Studies
One-year rat Appearance, overt behavior, body weight, and food consumption were recorded weekly. Ophthalmic examinations were conducted prior to dosing and at termination of the study. Blood samples collected during Weeks 7, 12, 26, 38, and 52 were analyzed for erythrocyte count, hematocrit, hemoglobin, leukocyte count, differential leukocyte count, urea nitrogen, aspartate aminotransferase, alanine aminotransferase, -y-glutamyl transferase, and creatinine. In addition, these samples were assayed for prothrombin time, activated partial thromboplastin time, glucose, cholesterol, total protein, sodium, potassium, and chloride at the Week-52 interval. Twenty-four-hour urine samples collected during the same intervals as above were analyzed for specific gravity, pH, protein, glucose, ketone, bilirubin, blood, and urobihnogen. At necropsy, organ weight was recorded for brain, liver, kidneys, adrenals, ovaries, heart, and testes with epididymides. Samples of these tissues and aorta, cecum, colon, duodenum, esophagus, eyes, femur, ileum, jejunum, larynx, lungs, mesenteric lymph node, thigh muscle, nasal cavity, pancreas, pituitary, prostate, rectum, salivary gland, sciatic nerve, seminal vesicles, skin, spleen, sternum, stomach, submaxillary lymph node, testes with epididymides, spinal cord, thymus, thyroid/parathyroid, trachea, urinary bladder, uterus, and vagina were processed for microscopic examination.
One-year dog. Appearance, overt behavior, and food consumption were recorded daily; body weight was recorded weekly. Ophthalmic examinations were conducted prior to dosing and during Weeks 12, 25, 38, and 51 of the study. Blood pressure, heart rate, and electrocardiograms were recorded prior to initiation of the study and 2 h postdose during Weeks 5, 12, 25, 38 , and 51 of the study. Blood samples collected prior to study initiation and during Weeks 6, 13, 26, 39, and 52 were analyzed for erythrocyte count, hematocrit, hemoglobin, leukocyte count, differential leukocyte count, prothrombin time, activated partial thromboplastin time, glucose, urea nitrogen, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total protein, creatinine, sodium, chloride, total bilirubin, potassium, triglycendes, and cholesterol. At necropsy, organ weight was recorded for adrenals, brain, heart, kidneys, liver, ovaries, pituitary, and testes with epididymides. Samples of these tissues and abdominal skin, adrenals, aorta, femur, brain, cecum, submaxillary lymph node, colon, duodenum, esophagus, eyes, gallbladder, ileum, jejunum, lungs, mesenteric lymph node, pancreas, parathyroids, pituitary, prostate, salivary gland, sciatic nerve, spleen, sternum, stomach, thigh muscle, spinal cord, thymus, thyroid, trachea, urinary bladder, and uterus were processed for microscopic evaluation.
Statistics
Acute Studies
If possible, LD50 values and their respective 95% confidence limits were calculated (Litchfield and Wilcoxon, 1949) .
Subchronic Studies
In the rat study, a one-way analysis of variance was performed on appropriate data sets using the general linear models procedure in the Statistical Analysis System 79 (SAS Institute, Inc., Cary, NC). In the dog study, Student's t test was used to evaluate significance between mean values. In both studies, all contrast were identified as the p £ 0.05 level.
Chronic Studies
In both studies, Student's / test was used to evaluate significance between mean values and all contrast were identified at the p ^ 0.05 level. 
RESULTS
Acute Studies
No signs of toxicity were observed in the mouse after oral administration of 3000 or 5000 mg/kg of felbamate; therefore, the oral LD50 was greater than 5000 mg/kg. After intraperitoneal administration of 375 to 775 mg/kg, clinical signs included rough hair coat, decreased activity, tremors (when handled), decreased muscle tone, ataxia, ptosis, prostration, and death. The incidence and time sequence of mortality is shown in Table 1 . The number of mice affected at each dose level and the severity and duration of the clinical signs were increased in a dose-related manner. The intraperitoneal LD50 in mice was 659 mg/kg for males and 681 mg/kg for females.
Ptosis, occurring within 15 min and lasting less than 1 h, was the only clinical sign observed in rats after oral administration of 3000 or 5000 mg/kg of felbamate. After intraperitoneal administration of 3000 to 5000 mg/kg in the male and 1000 to 3000 mg/kg in the female, clinical signs included diarrhea, decreased activity, decreased muscle tone, ataxia, ptosis, prostration, and death. The incidence and time sequence of mortality are shown in Table 1 . The number of rats affected at each dose level and the severity and duration of the clinical signs were increased in a dose-related manner. The intraperitoneal LD50 in rats was 4500 mg/kg for males and 1625 mg/kg for females; the oral LD50 was greater than 5000 mg/kg.
Subchronic Studies
Three-month rat. There were no abnormal clinical signs noted during the 3-month rat study and no drug-related deaths. However, mean body weight gain (Figs. 2 and 3) was decreased in females (22%) at 300 mg/kg and in males and females (25%) at 1000 mg/kg. All hematology and clinical chemistry parameters were within normal limits throughout the duration of the study. It was observed that rats receiving felbamate doses of 300 mg/kg (males only) and 1000 mg/kg (both sexes) had an increase in crystals in the urine. Absolute liver weight (Table 2 ) was increased at all dose levels in males and in the high-dose females. Liver weight relative to body weight was increased in mid-and high-dose males and females. In addition, relative kidney weight was increased in the males and females dosed at 1000 mg/kg. Mucoproteinaceous calculi were observed in the pelvis of the kidney of males receiving 1000 mg/kg.
Three-month dog. Ataxia, prostration with limb extension, tremors, emesis, and salivation were sporadically noted in some of the drug-treated dogs at all dose levels during the first 2 weeks of the study. These signs occurred within 2 h of drug administration and peaked at 4 to 6 hours after dosing. In a few cases, slight ataxia was evident up to 23 h postdose. Although body weight gain (Figs. 4 and 5 ) was reduced in all drug groups of both sexes, statistically significant changes were observed in mid-and high-dose males only. Alanine aminotransferase levels (Table 3) were higher than controls at all dose levels at some time during the study. Individual values in males were elevated to 630 U/L and in females to 196 U/L. In most cases, the increase in enzyme levels was transitory and decreased toward normal ranges even with continued dosing. Drug administration was never discontinued during the course of the study. Absolute and relative liver weight (Table 4 ) was higher than controls in all treated dogs. However, there were no histopathological lesions noted to explain the changes in enzyme levels or organ weight.
Chronic Studies
One-year rat. Based on food consumption, the overall mean drug consumption in the rat was 32.5, 156.3, and 637.7 mg/kg for the low-, mid-, and high-dose males and 32.9, 157.0, and 313.3 mg/kg for the low-, mid-, and high-dose females, respectively. There were no drug-induced changes in behavior or drug-related mortality in the 1-year rat study. Body weight gain (Figs. 6 and 7) was reduced in mid-and high-dose males and females. Based on changes in body and liver weight, females appeared to be more sensitive to the compound than males. Although the plasma level increased with dose, the increase was not proportional to dose (Table 5 ) and even though there was evidence of enzyme induction, the plasma drug levels did not decrease over time. Relative liver weight (Table 6 ) was increased in the high-dose males and the midand high-dose females. Centrolobular hepatic cell hypertrophy without degeneration or necrosis ("enzyme induction") was One-year dog. Ataxia, limb rigidity, salivation, emesis, and convulsions were noted in one male and two female dogs dosed at 300 mg/kg for the first 2 weeks of the 1-year dog study. One female at this dose continued to exhibit these signs sporadically during the study. Body weight gain (Figs. 8 and 9 ) was reduced in the low-and mid-dose drug groups compared to the control, while high-dose dogs lost weight during the study. As in the rat, plasma drug levels (Table 7) increased with dose but not in a proportional manner. Plasma drug levels were comparable between males and females and the drug levels did not decrease significantly over the course of the study. Alkaline phosphatase (Table 8 ) and alanine aminotransferase values (Table 9 ) were higher than controls in the dogs receiving 100 or 300 mg/kg. As in the case of the three-month dog study, individual enzyme values returned toward normal ranges even with continued dosing. Relative liver weight (Table 10) was increased in males and females dosed at 300 mg/kg. However, there were no histopathological lesions apparent in the liver to account for these enzyme changes.
DISCUSSION
The oral LD50 values in the mouse and rat indicate that felbamate is a relatively nontoxic compound. The 24-h mortality values were lower than the 14-day mortality values in both the mouse and the rat (Table 1) . At present, we have no data available to explain this effect. The difference in the intraperitoneal LD50 between male and female rats was a further indication that female rats are more sensitive to this compound. This effect in the rat was also noted in long-term
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1 Mean/standard error/number per group. * p < 0.05. elg studies but no similar sex-related effects were noted in the other species utilized in the safety studies. Body weight gain and/or food consumption was less than control animals in mice, rats, and dogs dosed with felbamate. This was a consistent drug-related effect noted in all studies with felbamate. The exact mechanism for this effect on body weight gain/food consumption is unknown at this time. However, the effect of felbamate on food consumption and body weight has also been noted in human clinical trials with felbamate (Sachdeo, 1992) . Crystalluria and mucoproteinaceous calculi of the renal pelvis were seen in the 3-month rat study at 1000 mg/kg. However, no pathological lesions of the kidney were observed in the 3-month rat nor in the 1-year rat study. No drug-related renal changes/lesions were noted in the dog studies conducted with felbamate. To date, there is no evidence in man that crystalluria has been a problem at human therapeutic doses (3600 mg/day). The only other consistent change noted in studies with felbamate was an increase in liver weight (both relative and absolute) in rats and dogs which was accompanied in some cases by increases in serum enzyme levels. Histopathological evidence of enzyme induction in the rat and elevation of alanine aminotransferase and/or alkaline phosphatase at doses of 100 mg/kg or greater in the dog indicate that felbamate may have a potential to cause liver toxicity. Although the enzyme levels were elevated in the dog, the serum values either plateau or decreased as dosing was continued. Despite relatively high (alkaline phosphatase 268 and alanine aminotransferase 168 U/L) enzyme levels at the time of necropsy, no histopathological lesions were observed in the liver of these dogs. Drug metabolism studies (Segelman et al., 1985) conducted in rats with felbamate confirm that the compound is a weak enzyme inducer; therefore, the elevated enzyme levels may be a reflection of enzyme induction rather than overt toxicity.
The results of the preclinical studies indicated that further studies in man were warranted. Although controlled clinical trials did not reveal any safety issues in man, postmarketing experience with felbamate revealed an association of the drug with liver failure and aplastic anemia. Whether these effects are related to felbamate alone or to an interaction with other medications is currently under investigation.
